In this review:
Tecentriq® (atezolizumab) is a humanised, engineered, IgG1 monoclonal antibody targeting programmed death ligand-1 (PD-L1).1 In New Zealand, atezolizumab in combination with carboplatin and etoposide is indicated (but not funded), for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).1 There has been limited treatment progress for patients with ES-SCLC over the past 20 years.2 Approval for atezolizumab in ES-SCLC was based on results of IMpower133, a phase III study showing that the addition of atezolizumab to carboplatin and etoposide resulted in significantly longer overall and progression-free survival than chemotherapy alone in the initial treatment of ES-SCLC.2 The aim of this review is to describe important safety and efficacy data for atezolizumab in patients with ES-SCLC. This publication has been commissioned by Roche Products (New Zealand) Limited.
Please login below to download this issue (PDF)